Bespak and H&T Presspart Ink Pact To Advance transition To low GWP Propellants

Bespak, a main contract development and manufacturing organization (CDMO) focused on orally breathed-in and nasal drug-device gadget blend items, and H&T Presspart, a pharmaceutical firm, declared a coordinated effort to speed up the business' change from existing pressurized Metered Dose Inhaler (pMDI) definitions to more environment well-disposed choices using low global warming potential (GWP) propellants.

The alliance will admit quickly to limited scope filling capacities in GMP conditions to help advancement programs and clinical trials with HFA-152a and HFO-1234ze charges. The joint effort uses H&T Presspart's mastery in inhalation product development, the organization's low GWP filling hardware and market-driving arrangement of componentry, and Bespak's skill and driving situation in valves as well as its plan improvement ability and completed item-producing capacity. The organization will speed up industry understanding and user progress in reformulating and commercialising items with a fundamentally lower ecological impression.

Chris Hirst, CEO of Bespak, commented: “We are committed to leading the transition to low GWP propellants in pMDIs, and in collaboration with H&T Presspart, we are proud to be able to offer a unique combination of capabilities and expertise to support our customers to transition as efficiently as possible. This partnership is significant in that we can offer development with both sustainable propellant options within a matter of weeks, no matter what the customer’s stage of product development when they commence work with us. Our goal is to transition as many pMDI products as possible to meet the requirements of evolving global legislation, and we believe in working together across the industry to achieve this goal - which not only helps protect the planet, but also safeguards patient access to inhaler options.”